237 related articles for article (PubMed ID: 38175465)
21. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
[TBL] [Abstract][Full Text] [Related]
22. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF; Kipps TJ; Eichhorst BF; D'Rozario J; Owen CJ; Assouline S; Lamanna N; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Mellink C; Chyla B; Panchal A; Lu T; Wu JQ; Jiang Y; Lefebure M; Boyer M; Kater AP
Blood; 2022 Aug; 140(8):839-850. PubMed ID: 35605176
[TBL] [Abstract][Full Text] [Related]
23. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
[TBL] [Abstract][Full Text] [Related]
25. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
26. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
27. [Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
Gauthier M; Comont T; Vergez F; Ysebaert L
Bull Cancer; 2018 Nov; 105(11):1042-1051. PubMed ID: 30243477
[TBL] [Abstract][Full Text] [Related]
28. The role of minimal residual disease in chronic lymphocytic leukemia.
Al-Sawaf O; Hallek M; Fischer K
Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
30. SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?
Thompson PA
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):205-209. PubMed ID: 34774461
[TBL] [Abstract][Full Text] [Related]
31. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
Heltai S; Ghia P; Scarfò L
Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
[TBL] [Abstract][Full Text] [Related]
32. Is there a role for anti-CD20 antibodies in CLL?
Shah HR; Stephens DM
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
34. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
35. Predictive role of NKCD56bright cells in monitoring the progression of chronic lymphocytic leukemia during treatment.
Blachnio K; Grygalewicz B; Woroniecka R; Rygier J; Pienkowska-Grela B; Rymkiewicz G; Kawiak J
Folia Histochem Cytobiol; 2022; 60(3):203-214. PubMed ID: 36045602
[TBL] [Abstract][Full Text] [Related]
36. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Chanan-Khan AA; Coutre SE; Davis RS; Eradat H; Fletcher CD; Gaballa S; Ghobadi A; Hamid MS; Hernandez-Ilizaliturri F; Hill B; Kaesberg P; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Ma S; Mato A; Mosse C; Schuster S; Siddiqi T; Stephens DM; Ujjani C; Wagner-Johnston N; Woyach JA; Ye JC; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2022 Jun; 20(6):622-634. PubMed ID: 35714675
[TBL] [Abstract][Full Text] [Related]
37. Eradication of minimal residual disease in chronic lymphocytic leukemia.
Schweighofer CD; Hallek M; Wendtner CM
Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
[TBL] [Abstract][Full Text] [Related]
38. Dual-targeted regimens for the frontline treatment of CLL.
Ujjani C
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):421-426. PubMed ID: 38066921
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.
Khan M; Siddiqi T
Curr Hematol Malig Rep; 2018 Dec; 13(6):525-533. PubMed ID: 30535947
[TBL] [Abstract][Full Text] [Related]
40. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
